Company Profile
Binney Street Capital is the venture fund of the Dana-Farber Cancer Institute, established to advance patient-centric innovation by investing in companies that leverage the Institute's technologies or expertise. The firm primarily focuses on oncology therapeutics and diagnostics, but also pursues opportunities across a variety of disease areas and sectors to maximize patient impact. They invest across the innovation life cycle, from company creation through early clinical validation, with a rigorous evaluation process to identify promising patient-centric ideas and teams that balance biological, technical, and translational risks.
Founded in 2021, Binney Street Capital was established to build on Dana-Farber's legacy of scientific breakthroughs and compassionate care. The initiative was launched to help support the development of new and advanced therapies for patients, investing in new research and technologies to treat incurable cancers. Investments are made from Dana-Farber investment funds, with returns intended to create a new revenue stream for additional Institute research. Luba Greenwood was initially tapped to lead the fund and its investments.
Binney Street Capital's portfolio companies span a range of healthcare industries and technologies across multiple disease areas. Notable investments include Matchpoint, which focuses on discovering precision small molecule medicines for immune diseases; NextPoint, which aims to unlock the potential of B7-H7 for precision oncology therapeutics; Precede, which is expanding precision medicine through high-resolution blood tests; and Predicta Biosciences, which develops molecular diagnostics for blood cancers and autoimmune diseases.
The team at Binney Street Capital brings together diverse expertise, united by a dedication to helping patients. Key members include Mary Tolikas, PhD, MBA, who serves as SVP and Chief Innovation Officer of Dana-Farber Cancer Institute and oversees Binney Street Capital, leveraging over 20 years of experience in scaling technology-based organizations. Steven Neier, PhD, is a Principal at Binney Street Capital, and Claire Hochleutner, BA, provides administrative support. The firm also leverages the expertise of top-tier researchers, clinicians, and business partners from Dana-Farber to identify and bridge transformative ideas from discovery to clinical validation.
News & Signals (0)
No linked news activity found for this company.